Recommendations for patients undergoing treatment with anti-TNF agents approved by the National Health Surveillance Agency for pediatric IBD (infliximab and adalimumab) infected with SARS-CoV-2 with or without the disease (COVID-19) (33):. This evidence concerns the gene TNF and COVID-19.